Welcome to our dedicated page for Moleculin Biotech news (Ticker: $MBRX), a resource for investors and traders seeking the latest updates and insights on Moleculin Biotech stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Moleculin Biotech's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Moleculin Biotech's position in the market.
Moleculin Biotech, Inc. (Nasdaq: MBRX) will report its Q1 2024 financial results on May 10, 2024. The company focuses on drug candidates for hard-to-treat tumors and viruses. A conference call and webcast to discuss the results will be held on May 13, 2024, at 8:30 AM ET.
Moleculin Biotech, Inc. reports positive interim data for Annamycin in treating acute myeloid leukemia (AML). The CRc rate reached 62% in 1st and 2nd line AML subjects, with a 45% CRc in the full MB-106 trial. The presentation of data supports advancing to a Phase 2 trial (MB-108) for potential New Drug Approval. A virtual AML Clinical Day was held on May 7, 2024. Key data shows promising results and progression towards registration for Annamycin in AML.
Moleculin Biotech, Inc. (Nasdaq: MBRX) will host a virtual AML Clinical Day featuring Dr. Martin Tallman, discussing the unmet medical needs in AML treatment, Annamycin, and the Company's AML clinical development program. The event will highlight the ongoing progress of Annamycin towards a pivotal AML study in 2024 for potential accelerated approval.
Moleculin Biotech, Inc. announced the formation of its Annamycin Scientific Advisory Board, appointing Dr. Martin Tallman as the inaugural clinician member. Dr. Tallman, an internationally renowned clinician, brings extensive experience in leukemia-targeting therapies. The company aims to advance the development of Annamycin, a promising treatment for AML and STS lung mets.
